The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

Trial ID: NCT06455293

Interventional - Phase 2 - Recruiting

The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.

Conditions

• Parkinson Disease
• Depression

Interventions

• Psilocybin
• Pimavanserin

Eligibility

Inclusion criteria

• Age 40 to 80
• Comfortable speaking and writing in English
• Have neurologist-diagnosed idiopathic Parkinson's disease (PD), Hoehn and Yahr stages 1 to 3 during an "on" phase (time when medication/DBS for parkinsonian motor feature, including bradykinesia and rigidity is in effect)
• Currently experiencing depressive symptoms
• Able to attend all in-person visits at UCSF as well as virtual visits
• Have a primary care provider, neurologist, or psychiatrist who is actively managing or coordinating

Exclusion criteria

• Psychotic symptoms involving loss of insight
• Significant cognitive impairment
• Regular use of medications that may have problematic interactions with psilocybin
• A health condition that makes this study unsafe or unfeasible, determined by study physicians

Sponsor

Joshua Woolley, MD, PhD

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows